PET/MRI (AXUMIN) STUDY OF MEN WITH HIGHLY SUSPICIOUS MRI LESIONS THAT SHOWED NO CLINICALLY SIGNIFICANT PROSTATE CANCER FOLLOWING MRI FUSION TARGETED BIOPSY

Brief description of study

The objective of this study is to find out if positron emission tomography (PET) imaging with 18-F fluciclovine (Axumin) identifies clinically significant prostate cancer in men like yourself who have a highly suspicious MRI lesion (PI-RADS score of 4 and 5 lesion) and the MRI-ultrasound fusion biopsy (MRFTB) does not show cancer.


Clinical Study Identifier: s18-00601
ClinicalTrials.gov Identifier: NCT03635866
Principal Investigator: Herbert Lepor
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.